← Back to the full Peptide Guide overview
Important Disclaimer — Read Before Using This Page
This information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide or hormone therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.
The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any therapy. Anyone starting a medication they have never taken before should take an extremely conservative approach.
Nothing on this page or in these videos should be taken as medical advice. These materials are provided only to help begin your research. All dosing and treatment decisions should be made between you and your medical providers after proper evaluation. We are not affiliated with any of the doctors whose videos appear on this page.
Retatrutide Investigational Compounded
Category: Triple GLP-1/GIP/Glucagon Receptor Agonist — Weight Management
How it works. Retatrutide is a triple receptor agonist that adds a third target—the glucagon receptor—to the GLP-1 and GIP activation of tirzepatide. Glucagon activation directly increases energy expenditure through hepatic and possibly brown-adipose-tissue mechanisms. In plain English: your body burns more calories at rest, in addition to eating less. That is the theoretical basis for the dramatic weight-loss results seen in early trials.
Regulatory status. Retatrutide is not yet FDA-approved. According to the manufacturer Eli Lilly, FDA approval is likely in early 2027. It remains investigational.
Research thoroughly and try various other medications prior to starting medications that are not yet FDA approved.
Discuss with your primary care physician before starting.
Side effects worth naming. Beyond the usual GLP-1 class effects (nausea, vomiting, constipation, fatigue), Phase 2 data flagged an unusual side effect called dysesthesia—abnormal skin sensations, including tingling or burning, particularly at higher doses. Heart-rate increases have been observed. Pancreatitis, gallbladder, thyroid, and MEN-2 class cautions all apply.
• Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389(6):514-26.
• Rosenstock J, et al. "Retatrutide for people with type 2 diabetes." Lancet. 2023;402(10401):529-44.
Recommended Videos
Dr. Ashley Froese — This Is Not Covered — Dr. Explains Why Retatrutide is KING of Fat Loss Peptides
Doctor Michael Mueller — Retatrutide Benefits Shock Medical Community (Official Release Date)
Dr. Jones, DC — Everything You Need To Know About Retatrutide in 2026 (WATCH BEFORE TAKING)
Video Sources & Independence
The videos linked on this page are provided solely for educational purposes. None of the physicians or channels featured are sponsored by, affiliated with, or compensated by NJ Weight Loss & Preventive Care Clinics, its physicians, or any individuals associated with our practice. We have selected these videos because they offer thoughtful, evidence-based discussion of mechanisms and clinical considerations. Viewers should evaluate all sources independently.
← Back to the full Peptide Guide overview · Peptide Dosing Reference →